Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor …
Abstract Objective Approximately 10%–15% patients with epidermal growth factor receptor
(EGFR) mutations harbor non-classical mutations. However, the effects of EGFR-tyrosine …
(EGFR) mutations harbor non-classical mutations. However, the effects of EGFR-tyrosine …
The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
SG Wu, CJ Yu, JCH Yang… - Therapeutic Advances in …, 2020 - journals.sagepub.com
Background and aims: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR
TKIs) are effective against classical EGFR mutations in lung cancer. However, their …
TKIs) are effective against classical EGFR mutations in lung cancer. However, their …
[HTML][HTML] Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor …
Results We analyzed 422 patients with EGFR-mutated advanced lung adenocarcinoma
receiving first-line gefitinib (n= 195, 46.2%), erlotinib (n= 123, 29.1%), or afatinib (n= 104 …
receiving first-line gefitinib (n= 195, 46.2%), erlotinib (n= 123, 29.1%), or afatinib (n= 104 …
Afatinib treatment in a large real‐world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation
CH Huang, JS Ju, TH Chiu, ACC Huang… - … Journal of Cancer, 2022 - Wiley Online Library
The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) afatinib improves
survival in nonsmall cell lung cancer (NSCLC) patients with EGFR mutation. We analysed …
survival in nonsmall cell lung cancer (NSCLC) patients with EGFR mutation. We analysed …
Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations
I Tanaka, M Morise, Y Kodama, A Matsui… - Lung …, 2019 - lungcancerjournal.info
Uncommon epidermal growth factor receptor (EGFR) mutations in non-small cell lung
cancer (NSCLC) are a heterogeneous group of genetic alterations that produce variable …
cancer (NSCLC) are a heterogeneous group of genetic alterations that produce variable …
Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression
AJ van der Wekken, JL Kuiper, A Saber, MM Terpstra… - PloS one, 2017 - journals.plos.org
Purpose To determine survival in afatinib-treated patients after treatment with first-
generation EGFR tyrosine kinase inhibitors (TKIs) and to study resistance mechanisms in …
generation EGFR tyrosine kinase inhibitors (TKIs) and to study resistance mechanisms in …
Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience
B Ricciuti, S Baglivo, A De Giglio… - … advances in respiratory …, 2018 - journals.sagepub.com
Epidermal growth factor receptor (EGFR) gene mutations identify a molecularly defined
subset of non-small cell lung cancer (NSCLC) patients who display an excellent sensitivity to …
subset of non-small cell lung cancer (NSCLC) patients who display an excellent sensitivity to …
A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer …
T Ninomiya, N Nogami, T Kozuki, D Harada, T Kubo… - Lung Cancer, 2018 - Elsevier
Objective In advanced epidermal growth factor receptor (EGFR)-mutant non-small-cell lung
cancer (NSCLC), treatment with afatinib, a second-generation EGFR-tyrosine kinase …
cancer (NSCLC), treatment with afatinib, a second-generation EGFR-tyrosine kinase …
Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs
W Brückl, A Tufman, RM Huber - Expert Review of Anticancer …, 2017 - Taylor & Francis
Introduction: Based on the results of several randomised controlled trials, epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have now replaced platinum-based …
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have now replaced platinum-based …
[HTML][HTML] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O'Byrne, L Zhang, V Hirsh… - Annals of …, 2017 - Elsevier
ABSTRACT Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib,
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …